title: Control of early Aspergillus mortality after lung transplantation: outcome and risk factors.
abstract: Historic treatment strategies in our institute had resulted in 10% Aspergillus mortality within the first posttransplant year. Despite nebulized amphotericin B (nAmB) prophylaxis, a significant incidence of Aspergillus infection, usually with poor outcome, is still reported. The aim of this single-center retrospective study was to evaluate the outcomes of patients receiving either standard nAmB or additional systemic caspofungin prophylaxis for selected high-risk patients. We also tried to define independent risk factors for either fungal infection or death. We followed 76 consecutive lung transplant patients performed at our center between 2002 and 2010 from the day of transplantation. The median follow-up duration was 953 days (2.6 years; range, 16-2,751 days). The endpoints were postoperative Aspergillus colonization or disease or death due to any cause. All patients received either nAmB deoxycholate (nAmBd, 15 patients) or nAmB lipid complex (nAmBLC, 61 patients). In addition, 33 patients also received short-term caspofungin prophylaxis. The overall cumulative mortality during the entire follow up was 14.5%. No clinically confirmed invasive Aspergillus infections (IPA) occurred during the first 2 postoperative years; however, there was 1 possible and 1 probable IPA. One patient died of bronchiolitis obliterans and IPA at 2 years 3 months. Twelve patients showed transient Aspergillus colonization. The antifungal prophylactic regimens were well tolerated. The risk factors for death were age >55 years and postoperative Aspergillus detection (P = .011 and P = .015, respectively). Preoperative Aspergillus colonization/disease was not a risk factor for death (P = 1.000). The strongest predictor of death was age >55 years, due to the elder probably being more susceptible to the adverse effects of immunosuppressants. Postoperative detection of Aspergillus still seems to be an indicator of a poorer outcome. Preoperative Aspergillus colonization is not necessarily a threat with prompt institution of antifungal prophylaxis.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Helsinki University Hospital, Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
authors.forename: K
authors.initials: K
authors.lastname: Lemström
authors.forename: R
authors.initials: R
authors.lastname: Suojaranta-Ylinen
authors.forename: T
authors.initials: T
authors.lastname: Martelius
authors.forename: A
authors.initials: A
authors.lastname: Harjula
authors.forename: J
authors.initials: J
authors.lastname: Sipponen
authors.forename: M
authors.initials: M
authors.lastname: Halme
authors.forename: A
authors.initials: A
authors.lastname: Piilonen
authors.forename: K
authors.initials: K
authors.lastname: Salmenkivi
authors.forename: V J
authors.initials: VJ
authors.lastname: Anttila
authors.forename: P
authors.initials: P
authors.lastname: Hämmäinen
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000401:mortality* / Q000517:prevention & control; D005500:Follow-Up Studies; D006801:Humans; D016040:Lung Transplantation; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B